P M O'Byrne1, N Naji, G M Gauvreau. 1. Firestone Institute for Respiratory Health, St. Joseph's Hospital and Department of Medicine, McMaster University, Hamilton, Ontario, Canada. obyrnep@mcmaster.ca
Abstract
BACKGROUND: Patients with severe refractory asthma have not achieved asthma control, even with high doses of ICS, usually in combination with LABAs and other maintenance treatments. OBJECTIVE: The most promising approaches currently under investigation are those which reduce airway eosinophils in patients with severe refractory asthma and a persisting airway eosinophilia. RESULTS: Monoclonal antibodies against IL-5 have been shown to improve lung function, improve asthma control, reduce exacerbation risk and allow reduction or elimination of maintenance oral corticosteroids in this subset of patients. Bronchial thermoplasty may provide benefit in improving control and reducing exacerbations in selected patients. The addition of the muscarinic antagonist, tiotropium also improves airflow obstruction, but its benefit on exacerbation risk is not yet established. Other developments being evaluated in severe refractory asthma are CXCR2 antagonists in patients with a persisting neutrophilic airway inflammation, and CRTh2 antagonists, both of which are small molecule antagonists, and hMabs against IL4 and IL-13. Finally, other approaches to reduce receptor numbers, using inhaled anti-sense, has shown to reduce allergen-induced airway eosinophilia, and combining different anti-sense against different targets may become a feasible treatment option. CONCLUSIONS: A variety of new treatment options are being investigated to help improve overall asthma control in patients with severe refractory asthma. These include medications to optimize lung function; bronchial thermoplasty to reduce airway smooth muscle in central airways; and those which target specific inflammatory cells or receptors of inflammatory mediators. CLINICAL RELEVANCE: Patients with severe refractory asthma have the greatest unmet treatment needs to improve asthma control and reduce exacerbation risk. New treatment approaches have been identified which will benefit subsets of these patients. Phenotyping patients is necessary to select those likely to benefit.
BACKGROUND:Patients with severe refractory asthma have not achieved asthma control, even with high doses of ICS, usually in combination with LABAs and other maintenance treatments. OBJECTIVE: The most promising approaches currently under investigation are those which reduce airway eosinophils in patients with severe refractory asthma and a persisting airway eosinophilia. RESULTS: Monoclonal antibodies against IL-5 have been shown to improve lung function, improve asthma control, reduce exacerbation risk and allow reduction or elimination of maintenance oral corticosteroids in this subset of patients. Bronchial thermoplasty may provide benefit in improving control and reducing exacerbations in selected patients. The addition of the muscarinic antagonist, tiotropium also improves airflow obstruction, but its benefit on exacerbation risk is not yet established. Other developments being evaluated in severe refractory asthma are CXCR2 antagonists in patients with a persisting neutrophilic airway inflammation, and CRTh2 antagonists, both of which are small molecule antagonists, and hMabs against IL4 and IL-13. Finally, other approaches to reduce receptor numbers, using inhaled anti-sense, has shown to reduce allergen-induced airway eosinophilia, and combining different anti-sense against different targets may become a feasible treatment option. CONCLUSIONS: A variety of new treatment options are being investigated to help improve overall asthma control in patients with severe refractory asthma. These include medications to optimize lung function; bronchial thermoplasty to reduce airway smooth muscle in central airways; and those which target specific inflammatory cells or receptors of inflammatory mediators. CLINICAL RELEVANCE: Patients with severe refractory asthma have the greatest unmet treatment needs to improve asthma control and reduce exacerbation risk. New treatment approaches have been identified which will benefit subsets of these patients. Phenotyping patients is necessary to select those likely to benefit.
Authors: Tao Huang; Meredith Hazen; Yonglei Shang; Meijuan Zhou; Xiumin Wu; Donghong Yan; Zhonghua Lin; Margaret Solon; Elizabeth Luis; Hai Ngu; Yongchang Shi; Arna Katewa; David F Choy; Nandhini Ramamoorthi; Erick R Castellanos; Mercedesz Balazs; Min Xu; Wyne P Lee; Marissa L Matsumoto; Jian Payandeh; Joseph R Arron; Jo-Anne Hongo; Jianyong Wang; Isidro Hötzel; Cary D Austin; Karin Reif Journal: JCI Insight Date: 2016-05-19
Authors: Aaron D Schuler; Courtney A Engles; Dean Y Maeda; Mark T Quinn; Liliya N Kirpotina; Winston N Wicomb; S Nicholas Mason; Richard L Auten; John A Zebala Journal: Bioorg Med Chem Lett Date: 2015-07-30 Impact factor: 2.823
Authors: Laura Keglowich; Michael Roth; Maria Philippova; Thérèse Resink; Gavin Tjin; Brian Oliver; Didier Lardinois; Sophie Dessus-Babus; Reinoud Gosens; Katrin Hostettler Haack; Michael Tamm; Peter Borger Journal: PLoS One Date: 2013-12-05 Impact factor: 3.240
Authors: David Price; Leonard Fromer; Alan Kaplan; Thys van der Molen; Miguel Román-Rodríguez Journal: NPJ Prim Care Respir Med Date: 2014-07-17 Impact factor: 2.871